Monique B Nilsson
Overview
Explore the profile of Monique B Nilsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
2808
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Patel S, Herynk M, Cascone T, Saigal B, Nilsson M, Tran H, et al.
J Thorac Oncol
. 2021 Jul;
16(12):2051-2064.
PMID: 34311109
Introduction: Subgroup analyses from clinical studies have suggested that among patients with metastatic NSCLC receiving chemotherapy, females may derive less benefit from the addition of the vascular endothelial growth factor...
12.
Stewart C, Gay C, Ramkumar K, Cargill K, Cardnell R, Nilsson M, et al.
J Thorac Oncol
. 2021 Jul;
16(11):1821-1839.
PMID: 34274504
Introduction: Coronavirus disease 2019 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which enters host cells through the cell surface proteins ACE2 and TMPRSS2. Methods:...
13.
Nilsson M, Robichaux J, Herynk M, Cascone T, Le X, Elamin Y, et al.
J Thorac Oncol
. 2020 Dec;
16(3):439-451.
PMID: 33309987
Introduction: The treatment of patients with EGFR-mutant NSCLC with vascular endothelial growth factor (VEGF) inhibitors in combination with EGFR inhibitors provides a greater benefit than EGFR inhibition alone, suggesting that...
14.
Nilsson M, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, et al.
Sci Transl Med
. 2020 Sep;
12(559).
PMID: 32878980
Acquired resistance to tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) remains a clinical challenge. Especially challenging are cases in which resistance emerges through EGFR-independent mechanisms, such as...
15.
Stewart C, Gay C, Ramkumar K, Cargill K, Cardnell R, Nilsson M, et al.
bioRxiv
. 2020 Jun;
PMID: 32577652
COVID-19 is an infectious disease caused by SARS-CoV-2, which enters host cells via the cell surface proteins ACE2 and TMPRSS2. Using a variety of normal and malignant models and tissues...
16.
Negrao M, Raymond V, Lanman R, Robichaux J, He J, Nilsson M, et al.
J Thorac Oncol
. 2020 Jun;
15(10):1611-1623.
PMID: 32540409
Introduction: Approximately 4% of NSCLC harbor BRAF mutations, and approximately 50% of these are non-V600 mutations. Treatment of tumors harboring non-V600 mutations is challenging because of functional heterogeneity and lack...
17.
Robichaux J, Elamin Y, Vijayan R, Nilsson M, Hu L, He J, et al.
Cancer Cell
. 2020 Mar;
37(3):420.
PMID: 32183953
No abstract available.
18.
Nilsson M, Le X, Heymach J
J Neuroimmune Pharmacol
. 2019 Dec;
15(1):27-36.
PMID: 31828732
Lung cancer results in more patient deaths each year than any other cancer type. Additional treatment strategies are needed to improve clinical responses to approved treatment modalities and prevent the...
19.
Robichaux J, Elamin Y, Vijayan R, Nilsson M, Hu L, He J, et al.
Cancer Cell
. 2019 Oct;
36(4):444-457.e7.
PMID: 31588020
We characterized the landscape and drug sensitivity of ERBB2 (HER2) mutations in cancers. In 11 datasets (n = 211,726), ERBB2 mutational hotspots varied across 25 tumor types. Common HER2 mutants...
20.
Le X, Puri S, Negrao M, Nilsson M, Robichaux J, Boyle T, et al.
Clin Cancer Res
. 2018 Sep;
24(24):6195-6203.
PMID: 30228210
Purpose: Osimertinib was initially approved for T790M-positive non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment of -mutant NSCLC. However, resistance mechanisms to osimertinib have been incompletely described....